·糖尿病临床研究·　

　　【摘要】 目的 评价那格列奈在亚洲T2DM人群中与其他口服药物相比的相对疗效及安全性。 方法 在数据库中进行文献检索并设定入选研究标准，对入选研究进行荟萃分析。 结果 43个研究纳入本研究。在降低HbA1c方面，那格列奈优于安慰剂及α-葡萄糖苷酶抑制剂(AGIs)，与磺脲类药物(SUs)相当，与瑞格列奈和米格列奈相当;在降低FPG方面，那格列奈劣于瑞格列奈，与安慰剂、AGIs、SUs和米格列奈相当;在降低餐后血糖方面，那格列奈与瑞格列奈、SUs、AGIs和米格列奈相当。 结论 本研究结果为那格列奈在亚洲T2DM人群中与其他口服药物相比的相对疗效和安全性提供了更全面的临床证据。

　　【关键词】 那格列奈;糖尿病，2型;糖化血红蛋白

Meta-analysis of the efficacy and safety of Nateglinide in Asian type 2 diabetes CAI Xiao-ling, LUO Ying-ying, HAN Xue-yao, et al. Department of Endocrinology & Metabolism, Peking University People’s Hospital, Beijing 100044, China

Corresponding author: JI Li-nong, E-mail: jiln@bjmu.edu.cn

　　【Abstract】 Objective To compare the efficacy and safety of nateglinide in Asian T2DM patients. Methods The MEDLINE®, EMBASE®, CENTRAL were searched and qualified studies were included. Results Totally 43 qualified studies were included. In terms of HbA1c decline, nateglinide treatment was superior to placebo (WMD:-0.28%, 95%CI: -0.41～-0.14) or α-glucosidase inhibitors (AGIs) (WMD:-0.27%, 95%CI: -0.53～-0.02), and was comparable with repaglinide or mitiglinide or sulfonylureas (SUs). In terms of fasting glucose lowering, nateglinide treatment was comparable with placebo or AGIs, or SUs or mitiglinide, but was inferior to repaglinide (WMD: 0.17mmol/L, 95%CI: 0.05～0.30). In terms of postprandial glucose lowering, nateglinide treatment was comparable with AGIs or repaglinide, or mitiglinide or SUs. In terms of fasting insulin secretion, nateglinide treatment was comparable with placebo or repaglinide or SUs. In terms of body weight lowering, nateglinide treatment was inferior to AGIs. Conclusion Both the efficacy and safety, as well as the progression of insulin secretion of nateglinide treatment were confirmed in this study.

　　【Key words】 Nateglinide; Diabetes mellitus, type 2; HbA1c